Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic FunctionSuleiman Massarweh, Rachel Schiff, C. Kent Osborne et al.|Cancer Research|2008Cited by 494
Insulin-Like Growth Factor-I Activates Gene Transcription Programs Strongly Associated With Poor Breast Cancer PrognosisChad J. Creighton, Adrian V. Lee, Angelo Casà et al.|Journal of Clinical Oncology|2008Cited by 261
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancerXiaoyong Fu, Rachel Schiff, Rinath Jeselsohn et al.|Proceedings of the National Academy of Sciences|2016Cited by 185
Development of Resistance to Targeted Therapies Transforms the Clinically Associated Molecular Profile Subtype of Breast Tumor XenograftsChad J. Creighton, Rachel Schiff, Suleiman Massarweh et al.|Cancer Research|2008Cited by 138
Reverse phase protein arrays in signaling pathways: a data integration perspectiveShixia Huang, Chad J. Creighton|Drug Design Development and Therapy|2015Cited by 68